

# Ian F Parney

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7038404/publications.pdf>

Version: 2024-02-01

161  
papers

10,494  
citations

31976

53  
h-index

34986

98  
g-index

162  
all docs

162  
docs citations

162  
times ranked

13885  
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. <i>Nature Medicine</i> , 2007, 13, 84-88.	30.7	1,177
2	Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC3): a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1049-1060.	10.7	840
3	Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. <i>Journal of Neurosurgery</i> , 2003, 99, 467-473.	1.6	571
4	Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. <i>Neuro-Oncology</i> , 2018, 20, 184-191.	1.2	443
5	Patterns of Care for Adults With Newly Diagnosed Malignant Glioma. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 557.	7.4	316
6	Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. <i>Journal of Neurosurgery</i> , 2003, 98, 1175-1181.	1.6	259
7	Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1537-1570.	4.9	253
8	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. <i>Neuro-Oncology</i> , 2010, 12, 351-365.	1.2	197
9	A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. <i>Nature Communications</i> , 2018, 9, 2949.	12.8	183
10	Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens. <i>Stem Cells</i> , 2009, 27, 1722-1733.	3.2	175
11	Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence. <i>Journal of Digital Imaging</i> , 2017, 30, 469-476.	2.9	167
12	Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. <i>Neuro-Oncology</i> , 2013, 15, 1058-1067.	1.2	163
13	Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation. <i>Acta Neuropathologica</i> , 2002, 103, 171-178.	7.7	160
14	NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1331-1345.	4.9	160
15	Residual Deep Convolutional Neural Network Predicts MGMT Methylation Status. <i>Journal of Digital Imaging</i> , 2017, 30, 622-628.	2.9	152
16	The p75 Neurotrophin Receptor Is a Central Regulator of Glioma Invasion. <i>PLoS Biology</i> , 2007, 5, e212.	5.6	150
17	Flow cytometry and in vitro analysis of human glioma-associated macrophages. <i>Journal of Neurosurgery</i> , 2009, 110, 572-582.	1.6	150
18	MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas. <i>Medical Physics</i> , 2016, 43, 2835-2844.	3.0	142

#	ARTICLE	IF	CITATIONS
19	Spinal Cord and Intradural-Extraparenchymal Spinal Tumors: Current Best Care Practices and Strategies. <i>Journal of Neuro-Oncology</i> , 2004, 69, 291-318.	2.9	132
20	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 757-772.	1.2	131
21	Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2008, 89, 97-103.	2.9	128
22	Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 1094-1104.	7.0	124
23	The role of LAT1 in 18F-DOPA uptake in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2013, 111, 11-18.	2.9	123
24	Glioma Immunology and Immunotherapy. <i>Neurosurgery</i> , 2000, 46, 778-792.	1.1	118
25	The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma. <i>Clinical Cancer Research</i> , 2008, 14, 2357-2362.	7.0	109
26	Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. <i>British Journal of Cancer</i> , 1999, 81, 638-646.	6.4	97
27	Management of diffuse low-grade gliomas in adults – use of molecular diagnostics. <i>Nature Reviews Neurology</i> , 2017, 13, 340-351.	10.1	95
28	Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. <i>Journal of Neurosurgery</i> , 2013, 118, 786-798.	1.6	92
29	Central Nervous System Cancers, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1191-1202.	4.9	89
30	Glioma Immunology and Immunotherapy. <i>Neurosurgery</i> , 2000, 46, 778-792.	1.1	89
31	Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV Î”M51 ) on Multifocal and Invasive Gliomas. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1546-1557.	6.3	88
32	Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. <i>Journal of Neurosurgery</i> , 2005, 102, 267-275.	1.6	87
33	Human Glioma Immunobiology in Vitro: Implications for Immunogene Therapy. <i>Neurosurgery</i> , 2000, 46, 1169-1178.	1.1	84
34	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1123-1132.	6.3	83
35	Current Chemotherapy for Glioblastoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2003, 9, 149-156.	2.0	80
36	Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. <i>Neuro-Oncology</i> , 2015, 17, 978-991.	1.2	80

#	ARTICLE	IF	CITATIONS
37	Idiopathic Cranial Hypertrophic Pachymeningitis Responsive to Antituberculous Therapy: Case Report. <i>Neurosurgery</i> , 1997, 41, 965-971.	1.1	78
38	Oligodendroglioma cell lines containing t(1;19)(q10;p10). <i>Neuro-Oncology</i> , 2010, 12, 745-755.	1.2	77
39	Radiosurgery to the Postoperative Surgical Cavity: Who Needs Evidence?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 486-493.	0.8	74
40	The Risk of Radiation-Induced Tumors or Malignant Transformation After Single-Fraction Intracranial Radiosurgery: Results Based on a 25-Year Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 919-923.	0.8	70
41	MR Elastography Analysis of Glioma Stiffness and IDH1-Mutation Status. <i>American Journal of Neuroradiology</i> , 2018, 39, 31-36.	2.4	70
42	Isolation and Analysis of Plasma-Derived Exosomes in Patients With Glioma. <i>Frontiers in Oncology</i> , 2019, 9, 651.	2.8	68
43	The reliability of YouTube videos in patients education for Glioblastoma Treatment. <i>Journal of Clinical Neuroscience</i> , 2018, 55, 1-4.	1.5	67
44	Granulocyte-Macrophage Colony-Stimulating Factor and B7-2 Combination Immunogene Therapy in an Allogeneic Hu-PBL-SCID/Beige Mouse Human Glioblastoma Multiforme Model. <i>Human Gene Therapy</i> , 1997, 8, 1073-1085.	2.7	66
45	Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. <i>Brain Pathology</i> , 2018, 28, 172-182.	4.1	64
46	Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. <i>American Journal of Neuroradiology</i> , 2017, 38, 678-684.	2.4	63
47	Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBM. <i>Canadian Journal of Neurological Sciences</i> , 2009, 36, 617-622.	0.5	62
48	Predictors of Surgical Site Infection Following Craniotomy for Intracranial Neoplasms: An Analysis of Prospectively Collected Data in the American College of Surgeons National Surgical Quality Improvement Program Database. <i>World Neurosurgery</i> , 2016, 88, 350-358.	1.3	62
49	The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction. <i>Neuro-Oncology</i> , 2020, 22, 967-978.	1.2	62
50	Gliomatosis cerebri: clinical characteristics, management, and outcomes. <i>Journal of Neuro-Oncology</i> , 2013, 112, 267-275.	2.9	61
51	Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane. <i>PLoS ONE</i> , 2017, 12, e0179012.	2.5	60
52	Surgical outcomes in recurrent glioma. <i>Journal of Neurosurgery</i> , 2013, 118, 1224-1231.	1.6	57
53	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. <i>Neuro-Oncology</i> , 2016, 18, 518-527.	1.2	57
54	Use of Movable High-Field-Strength Intraoperative Magnetic Resonance Imaging With Awake Craniotomies for Resection of Gliomas: Preliminary Experience. <i>Neurosurgery</i> , 2011, 69, 194-206.	1.1	56

#	ARTICLE	IF	CITATIONS
55	The NF- $\kappa$ B RelB Protein Is an Oncogenic Driver of Mesenchymal Glioma. PLoS ONE, 2013, 8, e57489.	2.5	52
56	Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications. Frontiers in Oncology, 2021, 11, 770561.	2.8	51
57	The role of radiotherapy in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 551-583.	2.9	50
58	Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years. Neuro-Oncology, 2013, 15, 1102-1110.	1.2	49
59	Association between the Cerebral Inflammatory and Matrix Metalloproteinase Responses after Severe Traumatic Brain Injury in Humans. Journal of Neurotrauma, 2013, 30, 1727-1736.	3.4	48
60	Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions?. Human Pathology, 2006, 37, 272-282.	2.0	47
61	Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience. Journal of Neuro-Oncology, 2010, 96, 403-408.	2.9	47
62	Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. Journal of Neuro-Oncology, 2011, 102, 255-260.	2.9	47
63	Antisense preendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhage. Journal of Neurosurgery, 1999, 90, 1105-1114.	1.6	44
64	Basic Concepts in Glioma Immunology. Advances in Experimental Medicine and Biology, 2012, 746, 42-52.	1.6	44
65	Adult Low-grade Glioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 612-619.	1.3	43
66	Preoperative Stereotactic Radiosurgery for Brain Metastases. Frontiers in Neurology, 2018, 9, 959.	2.4	41
67	Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators. Brain, 2020, 143, 3629-3652.	7.6	41
68	Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. Journal of Neuro-Oncology, 2006, 78, 71-80.	2.9	39
69	Adult Pilocytic Astrocytoma: An Institutional Series and Systematic Literature Review for Extent of Resection and Recurrence. World Neurosurgery, 2018, 110, 276-283.	1.3	38
70	Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Molecular Cancer Therapeutics, 2018, 17, 1893-1901.	4.1	37
71	Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. Neuro-Oncology, 2021, 23, 2042-2053.	1.2	37
72	Insurance correlates with improved access to care and outcome among glioblastoma patients. Neuro-Oncology, 2018, 20, 1374-1382.	1.2	34

#	ARTICLE	IF	CITATIONS
73	Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 639-651.	1.2	34
74	Awake Craniotomy, Electrophysiologic Mapping, and Tumor Resection With High-Field Intraoperative MRI. <i>World Neurosurgery</i> , 2010, 73, 547-551.	1.3	33
75	A Prospective Evaluation of the Temporal Matrix Metalloproteinase Response after Severe Traumatic Brain Injury in Humans. <i>Journal of Neurotrauma</i> , 2013, 30, 1717-1726.	3.4	33
76	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	2.8	32
77	The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2014, 120, 85-93.	2.9	30
78	Impact of Powdered Vancomycin on Preventing Surgical Site Infections in Neurosurgery: A Systematic Review and Meta-analysis. <i>Neurosurgery</i> , 2019, 84, 569-580.	1.1	30
79	Venous thromboembolic events in patients undergoing craniotomy for tumor resection: incidence, predictors, and review of literature. <i>Journal of Neurosurgery</i> , 2020, 132, 10-21.	1.6	30
80	The T2-FLAIR mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. <i>Neurosurgical Focus</i> , 2019, 47, E13.	2.3	30
81	Brain carcinoid metastases: outcomes and prognostic factors. <i>Journal of Neurosurgery</i> , 2013, 118, 889-895.	1.6	28
82	Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 137, 583-591.	2.9	26
83	Focal Encephalitis Following Varicella-Zoster Virus Reactivation Without Rash in a Healthy Immunized Young Adult. <i>Journal of Infectious Diseases</i> , 2014, 210, 713-716.	4.0	24
84	Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. <i>Neurotherapeutics</i> , 2016, 13, 226-236.	4.4	24
85	Improved technique for establishing short term human brain tumor cultures. <i>Journal of Neuro-Oncology</i> , 1999, 43, 1-10.	2.9	23
86	Long-term Outcomes and Role of Chemotherapy in Adults With Newly Diagnosed Medulloblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 1-7.	1.3	22
87	Dexmedetomidine and Mannitol for Awake Craniotomy in a Pregnant Patient. <i>Anesthesia and Analgesia</i> , 2015, 120, 1099-1103.	2.2	22
88	Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses. <i>PLoS ONE</i> , 2015, 10, e0125565.	2.5	22
89	Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 255-260.	0.8	22
90	Morbidity and mortality in elderly patients undergoing evacuation of acute traumatic subdural hematoma. <i>Neurosurgical Focus</i> , 2020, 49, E22.	2.3	22

#	ARTICLE	IF	CITATIONS
91	Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition. <i>Molecular Cancer Research</i> , 2022, 20, 938-948.	3.4	22
92	MULTIFOCAL COMPLEX GLIONEURONAL TUMOR IN AN ELDERLY MAN. <i>Neurosurgery</i> , 2009, 64, E1193-E1195.	1.1	21
93	ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi29-vi29.	1.2	21
94	Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 259-262.	2.1	20
95	Oxygen Is a Master Regulator of the Immunogenicity of Primary Human Glioma Cells. <i>Cancer Research</i> , 2011, 71, 6583-6589.	0.9	20
96	Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression. <i>Journal of Medical Imaging</i> , 2015, 2, 026001.	1.5	20
97	Predominance of M1 subtype among tumor-associated macrophages in phenotypically aggressive sporadic vestibular schwannoma. <i>Journal of Neurosurgery</i> , 2020, 133, 1637-1645.	1.6	20
98	Short non-coding RNA sequencing of glioblastoma extracellular vesicles. <i>Journal of Neuro-Oncology</i> , 2020, 146, 253-263.	2.9	20
99	Heparin-induced thrombocytopenia and thrombosis following subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 2000, 93, 136-139.	1.6	16
100	Cancer immunogene therapy: A review. <i>Journal of Biomedical Science</i> , 2003, 10, 37-43.	7.0	16
101	Stereotactic Radiosurgery in the Treatment of Recurrent CNS Lymphoma. <i>World Neurosurgery</i> , 2015, 84, 390-397.	1.3	16
102	Human Autologous In Vitro Models of Glioma Immunogene Therapy Using B7-2, GM-CSF, and IL12. <i>Canadian Journal of Neurological Sciences</i> , 2002, 29, 267-275.	0.5	15
103	Clinical outcomes of children and adults with central nervous system primitive neuroectodermal tumor. <i>Journal of Neuro-Oncology</i> , 2014, 120, 371-379.	2.9	15
104	Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells. <i>PLoS ONE</i> , 2019, 14, e0220569.	2.5	15
105	Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 341-352.	3.3	15
106	Principles of brain tumor surgery. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 104, 187-213.	1.8	14
107	Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2012, 110, 227-235.	2.9	14
108	Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience. <i>Journal of Neuro-Oncology</i> , 2017, 133, 339-346.	2.9	14

#	ARTICLE	IF	CITATIONS
109	Gamma Knife Stereotactic Radiosurgery for the Treatment of Primary and Metastatic Ocular Malignancies. <i>Stereotactic and Functional Neurosurgery</i> , 2017, 95, 363-368.	1.5	14
110	Cerebral blood volume and apparent diffusion coefficient “ Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116433.	0.6	14
111	Plasma extracellular vesicles as a source of biomarkers in traumatic brain injury. <i>Journal of Neurosurgery</i> , 2021, 134, 1921-1928.	1.6	13
112	Cranial Tumor Surgical Outcomes at a High-Volume Academic Referral Center. <i>Mayo Clinic Proceedings</i> , 2018, 93, 16-24.	3.0	11
113	Glioblastoma Recurrence Versus Treatment Effect in a Pathology-Documented Series. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 525-530.	0.5	10
114	Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI). <i>Journal of Neuro-Oncology</i> , 2022, 158, 349-357.	2.9	10
115	Clinical Trials in Brain Tumor Surgery. <i>Neuroimaging Clinics of North America</i> , 2010, 20, 409-424.	1.0	9
116	Editorial: Glioblastoma in the elderly. <i>Journal of Neurosurgery</i> , 2013, 118, 783-785.	1.6	9
117	Risk of internal carotid artery stenosis or occlusion after single-fraction radiosurgery for benign parasellar tumors. <i>Journal of Neurosurgery</i> , 2020, 133, 1388-1395.	1.6	9
118	336 Small RNA Sequencing of Glioblastoma Multiforme Extracellular Vesicles. <i>Neurosurgery</i> , 2016, 63, 198.	1.1	8
119	Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa105.	0.7	8
120	Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN- $\beta$ through PD-L1 and IDO1. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	8
121	Leptomeningeal Disease from Oligodendroglioma: Clinical and Molecular Analysis. <i>Canadian Journal of Neurological Sciences</i> , 2008, 35, 204-209.	0.5	7
122	Adjuvant radiation for WHO grade II and III intracranial meningiomas: insights on survival and practice patterns from a National Cancer Registry. <i>Journal of Neuro-Oncology</i> , 2020, 149, 293-303.	2.9	7
123	The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience. <i>Journal of Neuro-Oncology</i> , 2021, 155, 335-342.	2.9	7
124	Pediatric brain tumor cell lines exhibit miRNA-depleted, Y RNA-enriched extracellular vesicles. <i>Journal of Neuro-Oncology</i> , 2022, 156, 269-279.	2.9	7
125	Increased Frameless Stereotactic Accuracy With High-Field Intraoperative Magnetic Resonance Imaging. <i>Operative Neurosurgery</i> , 2012, 71, ons321-ons328.	0.8	6
126	Programmed death-ligand 1 (PD-L1) may play a role in malignant glioma infiltration. <i>Medical Hypotheses</i> , 2015, 85, 127-129.	1.5	6



#	ARTICLE	IF	CITATIONS
127	Nested Cohort Study to Identify Characteristics That Predict Near-Term Disablement From Lung Cancer Brain Metastases. <i>Archives of Physical Medicine and Rehabilitation</i> , 2017, 98, 303-311.e1.	0.9	6
128	Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	6
129	Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF. <i>Journal of Neuro-Oncology</i> , 2000, 47, 23-30.	2.9	5
130	Human Brain Tumor Cell Culture Characterization after Immunostimulatory Gene Transfer. <i>Neurosurgery</i> , 2002, 50, 1094-1102.	1.1	5
131	Human Brain Tumor Cell Culture Characterization after Immunostimulatory Gene Transfer. <i>Neurosurgery</i> , 2002, 50, 1094-1102.	1.1	5
132	Letter to the Editor: Survey of Academic U.S. Programs Regarding the Impact of the COVID-19 Pandemic on Clinical Practice, Education, and Research in Neurosurgery. <i>World Neurosurgery</i> , 2020, 140, 476-478.	1.3	5
133	Howard H. Hepburn and the Development of Skull Tongs for Cervical Spine Traction. <i>Neurosurgery</i> , 2000, 47, 1430-1433.	1.1	4
134	Progress in Malignant Glioma. <i>Journal of Neurosurgery</i> , 2004, 100, 1132-3; author reply 1133.	1.6	4
135	Treatment for posterior fossa dissemination of primary supratentorial glioma. <i>Journal of Neurosurgery</i> , 2007, 106, 567-574.	1.6	4
136	Clinical trials in neurosurgical oncology. <i>Journal of Neuro-Oncology</i> , 2014, 119, 569-576.	2.9	4
137	Higher temporal resolution multiband fMRI provides improved presurgical language maps. <i>Neuroradiology</i> , 2021, 63, 439-445.	2.2	4
138	Categorisation of patients based on immune profiles: a new approach to identifying candidates for response to checkpoint inhibitors. <i>Clinical and Translational Immunology</i> , 2021, 10, e1267.	3.8	4
139	Carbon fiducials for large choroidal melanoma treated with gamma knife radiosurgery. <i>Acta Ophthalmologica</i> , 2016, 94, e806-e807.	1.1	3
140	Carbon Fiducial Markers for Tumor Localization in Stereotactic Irradiation of Uveal Melanoma. <i>Ocular Oncology and Pathology</i> , 2021, 7, 368-375.	1.0	3
141	Journal of Neuro Oncology: immunotherapy for brain tumors. <i>Journal of Neuro-Oncology</i> , 2021, 151, 1-1.	2.9	2
142	Clinical utility of brain biopsy for presumed CNS relapse of systemic lymphoma. <i>Journal of Neurosurgery</i> , 2022, 136, 30-39.	1.6	2
143	Immune Response: Glioma-Associated Immunosuppression. , 2014, , 221-239.		2
144	Disparities in access to surgery for glioblastoma multiforme at high-volume Commission on Cancerâ€“accredited hospitals in the United States. <i>Journal of Neurosurgery</i> , 2021, , 1-10.	1.6	2

#	ARTICLE	IF	CITATIONS
145	Response to Letter to Editor. Neuro-Oncology, 2020, 22, 1706-1707.	1.2	1
146	Neurosurgical involvement in clinical trials for CNS tumors. Journal of Neuro-Oncology, 2021, 151, 367-373.	2.9	1
147	Chemotherapy Principles. , 2005, , 75-79.		1
148	Glioblastoma Multiforme. , 2005, , 143-148.		1
149	Long-Term Control after Radiosurgery for a Recurrent Supratentorial Primitive Neuroectodermal Tumor: A Case Report and Review of the Literature. Stereotactic and Functional Neurosurgery, 2021, 99, 267-269.	1.5	1
150	Does the dural resection bed need to be irradiated? Patterns of recurrence and implications for postoperative radiotherapy for temporal lobe gliomas. Neuro-Oncology Practice, 2021, 8, 190-198.	1.6	1
151	Introduction. Cranial surgery in geriatric patients. Neurosurgical Focus, 2020, 49, E1.	2.3	1
152	Letter: The Morbidity and Mortality of Surgery for Traumatic Brain Injury in Geriatric Patients: A Study of Over 100 000 Patient Cases. Neurosurgery, 2022, Publish Ahead of Print, .	1.1	1
153	In Reply to Prabhu et al. International Journal of Radiation Oncology Biology Physics, 2012, 84, 569-570.	0.8	0
154	Using comprehensive immune profiles to identify glioblastoma patients responsive to autologous dendritic cell vaccines. Cytotherapy, 2015, 17, S17.	0.7	0
155	Commentary. Operative Neurosurgery, 2016, 12, 339.	0.8	0
156	In Reply to the Letter to the Editor Regarding "A Surprise Sabbatical: How Mayo Clinic Neurosurgery Coped with COVID-19". World Neurosurgery, 2020, 144, 330.	1.3	0
157	Salvage Radiosurgery for Recurrent Supratentorial Primitive Neuroectodermal Tumors: A Single Institutional Series and Review of the Literature. Stereotactic and Functional Neurosurgery, 2021, 99, 405-411.	1.5	0
158	Intrinsic Posterior Fossa Brain Tumors. , 2005, , 875-891.		0
159	Myxopapillary Ependymomas. , 2005, , 493-496.		0
160	A Review on the Surgical Management of Insular Gliomas. Canadian Journal of Neurological Sciences, 2021, , 1-26.	0.5	0
161	Multiparametric analysis in GBM plasma extracellular vesicles (Evs) and surface marker expression profile.. Journal of Clinical Oncology, 2022, 40, 2038-2038.	1.6	0